Hussman Strategic Advisors Inc. Buys New Stake in Royalty Pharma PLC $RPRX

Key Points

• Hussman Strategic Advisors opened a new position in Royalty Pharma, purchasing 63,000 shares worth about $2.43 million in the fourth quarter.
• Significant insider selling was reported: CFO Terrance P. Coyne sold 34,791 shares (~$1.73 million) on April 28, and insiders have sold 382,705 shares (~$16.98 million) over the past 90 days, while insiders still own 18.84% of the stock.
• Analysts maintain a consensus "Buy" on RPRX with a MarketBeat consensus target of $50.33, and several firms have recently raised price targets (e.g., UBS to $57, Morgan Stanley to $63).

Hussman Strategic Advisors Inc. acquired a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The fund acquired 63,000 shares of the biopharmaceutical company's stock, valued at approximately $2,434,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its holdings in Royalty Pharma by 868.1% in the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company's stock worth $31,000 after buying an additional 790 shares in the last quarter. Private Trust Co. NA lifted its holdings in Royalty Pharma by 52.9% in the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 288 shares in the last quarter. Financial Consulate Inc. acquired a new position in Royalty Pharma in the 3rd quarter worth $35,000. Larson Financial Group LLC lifted its holdings in Royalty Pharma by 31.9% in the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 306 shares in the last quarter. Finally, Richardson Financial Services Inc. acquired a new position in Royalty Pharma in the 3rd quarter worth $54,000. Institutional investors and hedge funds own 54.35% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have commented on RPRX. Wall Street Zen lowered shares of Royalty Pharma from a "strong-buy" rating to a "buy" rating in a report on Saturday, February 14th. TD Cowen reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, February 27th. UBS Group boosted their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the stock a "buy" rating in a report on Tuesday, April 21st. The Goldman Sachs Group reiterated a "buy" rating on shares of Royalty Pharma in a report on Thursday, February 12th. Finally, Morgan Stanley boosted their price objective on shares of Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a report on Friday, April 10th. Six equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Royalty Pharma presently has a consensus rating of "Buy" and a consensus target price of $50.33.

Insider Buying and Selling at Royalty Pharma

In other news, CFO Terrance P. Coyne sold 34,791 shares of the business's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total value of $1,731,895.98. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 382,705 shares of company stock valued at $16,984,870. 18.84% of the stock is currently owned by insiders.

Royalty Pharma Price Performance

RPRX opened at $49.47 on Friday. The company has a 50-day moving average of $47.31 and a 200-day moving average of $42.41. The company has a market capitalization of $28.54 billion, a P/E ratio of 36.64, a PEG ratio of 3.16 and a beta of 0.40. Royalty Pharma PLC has a 1-year low of $31.97 and a 1-year high of $50.47. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.40 and a current ratio of 2.40.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last released its earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share for the quarter, topping the consensus estimate of $1.33 by $0.13. The company had revenue of $621.99 million during the quarter, compared to the consensus estimate of $839.97 million. Royalty Pharma had a net margin of 32.38% and a return on equity of 28.21%. Equities analysts expect that Royalty Pharma PLC will post 5.08 EPS for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $0.235 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.94 annualized dividend and a dividend yield of 1.9%. Royalty Pharma's payout ratio is presently 69.63%.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.